

Laurus Labs Limited

Corporate Office

2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320



November 21, 2019

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,

Sub: Press Release - Laurus Labs completes USFDA, pre-approval inspection (PAI), for an API manufactured at its units 1&3, Visakhapatnam

The Company is pleased to announce that it has completed the USFDA, pre-approval inspection (PAI) for an API manufactured at its Units 1&3, located at J N Pharma City, Parawada, Visakhapatnam, Andhra Pradesh, with three observations, which are procedural in nature and no data integrity issues were observed in the inspection.

The inspection was carried out from November 18, 2019 to November 21, 2019.

A press release to this extent is also enclosed for your information and records.

Thanking you,

Yours sincerely,
For Laurus Labs Limited

ve k
V V Ravi Kumar
Executive Director and
Chief Financial Officer



Encl: As above

LAURUS LABS COMPLETES USFDA, PRE APPROVAL INSPECTION (PAI), FOR AN API MANUFACTURED AT ITS UNITS 1&3, VISAKHAPATNAM.

Hyderabad, November 21, 2019, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010)

Laurus Labs Limited, a leading research and development driven pharmaceutical company has completed the USFDA, Pre Approval Inspection (PAI) for an API manufactured at its Units 1&3, located at J N Pharma City, Parawada, Visakhapatnam, Andhra Pradesh, with three observations, which are procedural in nature.

No data integrity issues were observed in the inspection. The inspection was carried out from 18 November, 2019 – 21 November, 2019.

About Laurus Labs Limited

Laurus Labs is a leading research driven Pharmaceutical Manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology. We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe and Low Middle Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business. Most of our manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA etc. Our approach remains to identify and invest ahead of time with strategic investments in State-of-the-Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high volume products. **Corporate Identification No: L24239AP2005PLC047518**

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Pavan Kumar N
Laurus Labs Ltd.
Tel: +91 40 3980 4380
Email: mediarelations@lauruslabs.com



DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.